![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NIH Shoots Down Request to Override Xtandi Patent
NIH Shoots Down Request to Override Xtandi Patent
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
June 24, 2016
The U.S. National Institutes of Health shot down a request from nonprofit groups to bypass the patent for Astellas Pharmaceuticals’ prostate drug Xtandi in an effort to lower the drug’s price.
In a letter dated June 20, the agency noted that there is no information suggesting that Xtandi is in short supply and has decided against the request for a march-in investigation.
In April, Knowledge Ecology International petitioned the agency to exercise march-in rights — a method used to override the exclusivity rights to a patent developed with public funding — over the price of Xtandi. Xtandi has a list price of $88 per pill, or $129,000 per year.
Upcoming Events
-
21Oct